Gilead Sciences' (GILD) Treatment of Pulmonary Arterial Hypertension Granted Orphan Drug Status by FDA

August 24, 2016 8:29 AM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Gilead Sciences' (NASDAQ: GILD) treatment of pulmonary arterial hypertension was granted orphan drug status by the FDA. The generic name is ambrisentan/tadalafil fixed combination.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, FDA

Add Your Comment